Diamyd Medical refrains from enforcing the underwriting agreements in the rights issue and extends the subscription period
Diamyd Medical AB (publ) ("Diamyd Medical" or the "Company") has decided to refrain from enforcing the underwriting agreements entered into with a number of external investors in connection with the rights issue. The reason is that there is substantial uncertainty as to whether the underwriting agreements are fully legally binding and could be enforced by the Company. In light of this, Diamyd Medical has decided to extend the subscription period in the rights issue and to draw up a supplementary prospectus. THIS PRESS RELEASE MAY NOT BE RELEASED, PUBLICATED OR DISTRIBUTED, DIRECTLY OR